Tezepelumab
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine at the top of the inflammatory cascade that drives IgE production, eosinophil activation, and Th2 inflammation in asthma and atopic dermatitis. It is approved as add-on maintenance therapy for severe asthma regardless of eosinophil phenotype, making it unique among biologics in treating non-eosinophilic asthma. By blocking upstream TSLP, it broadly suppresses multiple allergic and non-allergic inflammatory pathways.
Terapötik Alanlar
Etki Mekanizması
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine at the top of the inflammatory cascade that drives IgE production, eosinophil activation, and Th2 inflammation in asthma and atopic dermatitis. It is approved as add-on maintenance therapy for severe asthma regardless of eosinophil phenotype, making it unique among biologics in treating non-eosinophilic asthma. By blocking upstream TSLP, it broadly suppresses multiple allergic and non-allergic inflammatory pathways.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Tezepelumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707229. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tezepelumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tezepelumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tezepelumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tezepelumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tezepelumab"></drugfyi-drug>